Resalis Therapeutics presented preclinical data at TIDES Europe on an antisense oligonucleotide (ASO) targeting miR‑22, which the company says drives metabolic reprogramming and sustained weight loss in animal models. Company scientists argue the ASO acts on fat metabolism at source rather than suppressing appetite, differentiating it from GLP‑1 receptor agonists and addressing concerns about muscle, bone and energy loss associated with peptide therapies. Resalis CSO Riccardo Panella traced the program’s origins to miRNA biology and described protective effects in knockout mice and obesity phenotypes in overexpression models. The program remains preclinical; Resalis positions the ASO as a potential alternative or complement to current obesity medicines and will need safety, tolerability and long‑term metabolic outcome data to advance into human trials.